

MAY 3 1 2006

Section 5 – 510(k) Summary or 510(k) Statement

K061025

**I. General Information**

Submitter: Accutech Medical Technologies, Inc.  
13-550 Trillium Drive  
Kitchener, Ontario N2R 1K3  
Canada

Contact Person: David Stiles  
Director of Regulatory Affairs and Quality Assurance

Summary Preparation Date: April 10, 2006

**II. Names**

Device Names: Accutech EndoLite Probe

Primary Classification Names: Accessory for, Laser Powered Surgical Instruments

**III. Predicate Devices**

- Lumenis EndoOcular Probes (K052526, K931072, K990174, K022181)
- CeramOptec/BioLitec EndoProbe (K964751)
- CeramOptec MegaBeam Fiber Optic Delivery System (K980389, K943445)

**IV. Product Description**

The Accutech EndoLite Probe is comprised of the following main components:

- A glass fiber optic protected by a medical grade stainless steel needle and handle at the distal (patient contact) end and by a plastic jacket at the proximal (laser connection) end; and
- A universal SMA laser connector.

The Accutech EndoLite Probe is provided as a sterile, single use 532-659 nm laser energy delivery system device (accessory). The universal SMA connector at the proximal end of the optical fiber delivery device is designed to be attached to the optical fiber Laser Port of the compatible 532-659 nm laser system with universal SMA compatibility that has been qualified by Accutech Medical Technologies, Inc. for use with the Accutech EndoLite Probe.

**V. Indications for Use**

The Accutech EndoLite Probe is intended for use in the treatment of ocular pathology.

The Accutech EndoLite Probe is indicated for use in ocular photocoagulation of the anterior and posterior segment for the indications for use cleared for the 532-659 nm laser system(s) with which it is compatible for use.

**VI. Rationale for Substantial Equivalence**

The Accutech EndoLite Probe shares the same or similar indications for use, device operation, overall technical and functional capabilities, and therefore is substantially equivalent to the predicate devices.

**VII. Safety and Effectiveness Information**

The review of the indications for use and technical characteristics provided demonstrates that the Accutech EndoLite Probe is substantially equivalent to the predicate devices.

**VIII. Conclusion**

The Accutech EndoLite Probe was found to be substantially equivalent to the predicate devices.

The Accutech EndoLite Probe shares the same or similar indications for use, similar design features, and functional features with, and thus is substantially equivalent to, the predicate devices.



Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

MAY 3 1 2006

Accutech Medical Technologies, Inc.  
% AL Voss Associates  
Ms. Anne Worden  
Regulatory Consultant  
3637 Bernal Avenue  
Pleasanton, California 94566

Re: K061025

Trade/Device Name: Accutech EndoLite Probe

Regulation Number: 21 CFR 878.4810

Regulation Name: Laser surgical instrument for use in general and plastic surgery and  
in dermatology

Regulatory Class: II

Product Code: GEX

Dated: April 10, 2006

Received: April 13, 2006

Dear Ms. Worden:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21


Page 2 – Ms. Anne Worden

CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,



Mark N. Melkenson  
Director  
Division of General, Restorative  
and Neurological Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

Indications for Use Statement

510(k) Number (if known): K06 12061025

Device Name: Accutech EndoLite Probe

Indications for Use:

The Accutech EndoLite Probe is intended for use in the treatment of ocular pathology.

The Accutech EndoLite Probe is indicated for use in ocular photocoagulation of the anterior and posterior segment for the indications for use cleared for the 532-659 nm laser system(s) with which it is compatible for use.

Prescription Use   
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDH, Office of Device Evaluation (ODE)



**(Division Sign-Off)**

**Division of General, Restorative,  
and Neurological Devices**

**510(k) Number** K061025

Page 1 of 1